問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Division of General Surgery

Far Eastern Memorial Hospital (非在職)

Division of Hematology & Oncology

更新時間：2025-02-26

葉坤輝Yeh, Kun-Huei
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

Recruiting Trial

97Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉坤輝

List

204Cases

2021-04-01 - 2024-03-15

Phase I

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2021-07-01 - 2022-08-31

Phase I/II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2026-06-01 - 2032-12-31

Phase III

Not yet recruiting
A phase 3, randomized, multicenter, open-label trial comparing velzatinib (GSK6042981) with imatinib in participants with previously untreated metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

  • Condition/Disease

    Previously untreated metastatic and/or unresectable gastrointestinal stromal tumors

  • Test Drug

    Imatinib tablets 100mg Imatinib tablets 400mg Velzatinib (GSK6042981) Tablets 100mg

Participate Sites
5Sites

Not yet recruiting1Sites

2026-07-01 - 2028-11-30

Phase II

Not yet recruiting
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Advanced Gastrointestinal (GI) Cancers

  • Condition/Disease

    Gastrointestinal Cancers

  • Test Drug

    Rina‑S

Participate Sites
5Sites

Not yet recruiting1Sites

2018-07-30 - 2020-09-30

Phase III

Completed
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Condition/Disease

    Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer Metastatic Gastric Adenocarcinoma or Cancer Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
9Sites

Recruiting6Sites

Terminated1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

2022-02-01 - 2022-04-06

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2022-04-01 - 2028-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-26 - 2029-10-29

Phase III

Not yet recruiting
A phase III, double-blind, placebo-controlled, randomized trial was conducted to evaluate the efficacy and safety of ASP3082 combined with mFOLFIRINOX or NALIRIFOX as first-line treatment in participants with KRAS G12D-mutant metastatic pancreatic adenocarcinoma.

  • Condition/Disease

    Metastatic pancreatic adenocarcinoma

  • Test Drug

    "Xinghui" Xingrui Platinum Intravenous Injection 5 mg/mL ASP3082 Haofu Injection 50 mg Anengde Liposome Injection Kefeiyan Injection 10 mg Anticancer Intravenous Concentrate Erenodin Concentrate Injection Fulinya Injection 10 mg/mL Yilinuo Intravenous Infusion Solution Yile Platinum Injection 5 mg/mL

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-07-01 - 2028-05-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2022-07-06 - 2026-12-31

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

1 2 3 4 5 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB